General Information of Drug Transporter (DT)
DT ID DTD0010 Transporter Info
Gene Name SLC22A1
Transporter Name Organic cation transporter 1
Gene ID
6580
UniProt ID
O15245
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.7 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 5.7 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT1
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 13 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Quinine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 22.9 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Quinine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 17.5 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Quinine inhibits the transportation of YM155 by SLC22A1 (IC50 = 7.11 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Quinine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tetraethylammonium Investigative Drug
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 469.7 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT1
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 216 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 158 microM) [7]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 167 microM) [8]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1 [9]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the transportation of Metformin by SLC22A1 (IC50 = 0.62 microM) [10]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Verapamil inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2.9 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Verapamil inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.23 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Verapamil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 493 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1231 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Metformin inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2820 microM) [11]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Metformin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6], [12]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Estradiol Approved Drug
DT Modulation Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 5.73 microM) [13]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Estradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Estradiol inhibits the activity of SLC22A1 [13]
Exogenous Factor Repaglinide Approved Drug
DT Modulation Repaglinide inhibits the transportation of Metformin by SLC22A1 (IC50 = 1.6 microM) [14]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OCT1
DT Modulation Repaglinide inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.8 microM) [14]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OCT1
DT Modulation Repaglinide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clonidine Approved Drug
DT Modulation Clonidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.5 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Clonidine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 0.55 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Clonidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Phenformin Drug Withdrawn
DT Modulation Phenformin inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 13 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Phenformin inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 23 microM) [11]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Phenformin inhibits the activity of SLC22A1 [11]
Exogenous Factor Ranitidine Approved Drug
DT Modulation Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 33 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Ranitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cimetidine Approved Drug
DT Modulation Cimetidine inhibits the transportation of YM155 by SLC22A1 (IC50 = 149 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Cimetidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6], [12]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Cimetidine inhibits the activity of SLC22A1 [11]
Exogenous Factor Prazosin Approved Drug
DT Modulation Prazosin inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.56 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Prazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Prazosin inhibits the activity of SLC22A1 [13], [17]
Exogenous Factor Nicotine Approved Drug
DT Modulation Nicotine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Nicotine inhibits the transportation of Tetraethylammonium by SLC22A1 [15]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Nicotine inhibits the activity of SLC22A1 [16]
Exogenous Factor Phenoxybenzamine Approved Drug
DT Modulation Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 2.72 microM) [13]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Phenoxybenzamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Progesterone Approved Drug
DT Modulation Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 3.05 microM) [13]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Progesterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Vecuronium Approved Drug
DT Modulation Vecuronium inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (Ki = 120 microM) [18]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Vecuronium inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 232 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Fenamiphos Natural Product
DT Modulation Fenamiphos inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 27.5 microM) [19]
Affected Drug/Substrate 4',6'-diamidino-2-phenylindole Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Fenamiphos inhibits the transportation of Dopamine by SLC22A1 (IC50 = 9.2 microM) [19]
Affected Drug/Substrate Dopamine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Phosmet Natural Product
DT Modulation Phosmet inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 10.4 microM) [19]
Affected Drug/Substrate 4',6'-diamidino-2-phenylindole Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Phosmet inhibits the transportation of Dopamine by SLC22A1 (IC50 = 7.1 microM) [19]
Affected Drug/Substrate Dopamine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Disopyramide Approved Drug
DT Modulation Disopyramide inhibits the transportation of 4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+) by SLC22A1 (IC50 = 81.7 microM) [6]
Affected Drug/Substrate 4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+) Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Disopyramide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Amitriptyline Approved Drug
DT Modulation Amitriptyline inhibits the transportation of Metformin by SLC22A1 (IC50 = 6.99 microM) [10]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Amitriptyline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Glibenclamide Approved Drug
DT Modulation Glibenclamide inhibits the transportation of Metformin by SLC22A1 (IC50 = 199 microM) [10]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Glibenclamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Simvastatin Approved Drug
DT Modulation Simvastatin inhibits the transportation of Metformin by SLC22A1 (IC50 = 89 microM) [10]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Simvastatin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Amantadine Approved Drug
DT Modulation Amantadine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 236 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Amantadine inhibits the transportation of YM155 by SLC22A1 (IC50 = 39.6 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Atropine Approved Drug
DT Modulation Atropine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.2 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Atropine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Famotidine Approved Drug
DT Modulation Famotidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Famotidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Memantine Approved Drug
DT Modulation Memantine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 3.7 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Memantine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ritonavir Approved Drug
DT Modulation Ritonavir inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 14 microM) [21]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Ritonavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 5.18 microM) [22]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Acebutolol Approved Drug
DT Modulation Acebutolol inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 95.8 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Acebutolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Decynium 22 Investigative Drug
DT Modulation Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.9 microM) [8]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2.73 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Indinavir Approved Drug
DT Modulation Indinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 61.7 microM) [22]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
DT Modulation Indinavir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Corticosterone Investigative Drug
DT Modulation Corticosterone inhibits the transportation of YM155 by SLC22A1 (IC50 = 8.89 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Corticosterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Procainamide Approved Drug
DT Modulation Procainamide inhibits the transportation of YM155 by SLC22A1 (IC50 = 51.3 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Procainamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tubocurarine Approved Drug
DT Modulation Tubocurarine inhibits the transportation of YM155 by SLC22A1 (IC50 = 62.4 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Tubocurarine inhibits the activity of SLC22A1 [23]
Exogenous Factor Pancuronium Approved Drug
DT Modulation Pancuronium inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 [18]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT1
DT Modulation Pancuronium inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Amiloride Approved Drug
DT Modulation Amiloride inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Amiloride inhibits the activity of SLC22A1 [23]
Exogenous Factor Ethopropazine Approved Drug
DT Modulation Ethopropazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [12]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Ethopropazine inhibits the transportation of Metformin by SLC22A1 [12]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Rifampicin Approved Drug
DT Modulation Rifampicin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tacrine Approved Drug
DT Modulation Tacrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [12]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Tacrine inhibits the transportation of Metformin by SLC22A1 [12]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Vitamin B1 Approved Drug
DT Modulation Vitamin B1 inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [12]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation Vitamin B1 inhibits the transportation of Tetraethylammonium by SLC22A1 [15]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Rifampin Approved Drug
DT Modulation Rifampicin induces the activity of SLC22A1 [24]
Exogenous Factor Pioglitazone Approved Drug
DT Modulation Pioglitazone inhibits the transportation of Metformin by SLC22A1 (IC50 = 185 microM) [10]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Diphenhydramine Approved Drug
DT Modulation Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 3.4 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Butylscopolamine Approved Drug
DT Modulation Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor YM155 Drug in Phase 2 Trial
DT Modulation YM155 inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 23.8 microM) [5]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Etilefrine Drug Withdrawn
DT Modulation Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 447 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Phencyclidine Investigative Drug
DT Modulation Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 4.4 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Dizocilpine Discontinued Drug
DT Modulation Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 80.5 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cocaine Approved Drug
DT Modulation Cocaine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 85 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ketamine Approved Drug
DT Modulation Ketamine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 114.5 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Dextroamphetamine Approved Drug
DT Modulation Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 202 microM) [20]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Antiparasitics Discontinued Drug
DT Modulation Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 7.4 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT1
Exogenous Factor Pentamidine Approved Drug
DT Modulation Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16.4 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT1
Exogenous Factor Cyclopiazonic acid Mycotoxins
DT Modulation Cyclopiazonic acid inhibits the transportation of Organic cation by SLC22A1 (IC50 > 1000 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Fumonisin B1 Mycotoxins
DT Modulation Fumonisin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 > 1000 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Zearalenone Mycotoxins
DT Modulation Zearalenone inhibits the transportation of Organic cation by SLC22A1 (IC50 = 0.62 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Alpha-zearalenol Mycotoxins
DT Modulation Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A1 (IC50 = 1.7 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Citreoverdine Natural Product
DT Modulation Citreoverdine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Citrioveridine Mycotoxins
DT Modulation Citrioveridine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Aflatoxin B1 Mycotoxins
DT Modulation Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 = 64.4 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Gliotoxin Mycotoxins
DT Modulation Gliotoxin inhibits the transportation of Organic cation by SLC22A1 (IC50 = 584 microM) [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Patulin Mycotoxins
DT Modulation Patulin inhibits the transportation of Organic cation by SLC22A1 [25]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT1
Exogenous Factor Dieldrin Natural Product
DT Modulation Dieldrin inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.9 microM) [26]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-OCT1
Exogenous Factor Lindane Approved Drug
DT Modulation Lindane inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 1.52 microM) [26]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-OCT1
Exogenous Factor Saquinavir Approved Drug
DT Modulation Saquinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 8.26 microM) [22]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Nelfinavir Approved Drug
DT Modulation Nelfinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.8 microM) [22]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Midazolam Approved Drug
DT Modulation Midazolam inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 3.7 microM) [4]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the transportation of Verapamil by SLC22A1 (IC50 = 12.5 microM) [27]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-OCT1
Exogenous Factor Allethrin Natural Product
DT Modulation Allethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 2.6 microM) [28]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tetramethrin Natural Product
DT Modulation Tetramethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 4.9 microM) [28]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor N-methylpyridinium Drug in Preclinical Test
DT Modulation N-methylpyridinium inhibits the transportation of YM155 by SLC22A1 (IC50 = 30.4 microM) [5]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Benzyl alcohol Approved Drug
DT Modulation Benzyl alcohol inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.018 microM) [29]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Exogenous Factor Acarbose Approved Drug
DT Modulation Acarbose inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Acetaminophen Approved Drug
DT Modulation Acetaminophen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Acetylcysteine Approved Drug
DT Modulation Acetylcysteine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Acyclovir Approved Drug
DT Modulation Acyclovir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Allopurinol Approved Drug
DT Modulation Allopurinol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ampicillin Approved Drug
DT Modulation Ampicillin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Amsacrine Approved Drug
DT Modulation Amsacrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Apomorphine Approved Drug
DT Modulation Apomorphine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Aspirin Approved Drug
DT Modulation Aspirin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Atenolol Approved Drug
DT Modulation Atenolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Azathioprine Approved Drug
DT Modulation Azathioprine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Baclofen Approved Drug
DT Modulation Baclofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Budesonide Approved Drug
DT Modulation Budesonide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Buspirone Approved Drug
DT Modulation Buspirone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Caffeine Approved Drug
DT Modulation Caffeine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Candesartan Approved Drug
DT Modulation Candesartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Captopril Approved Drug
DT Modulation Captopril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Carbamazepine Approved Drug
DT Modulation Carbamazepine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Carisoprodol Approved Drug
DT Modulation Carisoprodol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Celecoxib Approved Drug
DT Modulation Celecoxib inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cephalexin Approved Drug
DT Modulation Cephalexin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cetirizine Approved Drug
DT Modulation Cetirizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Chloramphenicol Approved Drug
DT Modulation Chloramphenicol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Chloroquine Approved Drug
DT Modulation Chloroquine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Chlorpromazine Approved Drug
DT Modulation Chlorpromazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Chlorprothixene Approved Drug
DT Modulation Chlorprothixene inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Chlorzoxazone Approved Drug
DT Modulation Chlorzoxazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Citalopram Approved Drug
DT Modulation Citalopram inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clemastine Approved Drug
DT Modulation Clemastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clindamycin Approved Drug
DT Modulation Clindamycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clodronate Approved Drug
DT Modulation Clodronate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clomipramine Approved Drug
DT Modulation Clomipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clotrimazole Approved Drug
DT Modulation Clotrimazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Clozapine Approved Drug
DT Modulation Clozapine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Codeine Approved Drug
DT Modulation Codeine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Colchicine Approved Drug
DT Modulation Colchicine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cyclophosphamide Approved Drug
DT Modulation Cyclophosphamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cyclosporine Approved Drug
DT Modulation Cyclosporine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cyproterone Approved Drug
DT Modulation Cyproterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Cysteamine Approved Drug
DT Modulation Cysteamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Denopamine Approved Drug
DT Modulation Denopamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Desipramine Approved Drug
DT Modulation Desipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Diazepam Approved Drug
DT Modulation Diazepam inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Diclofenac Approved Drug
DT Modulation Diclofenac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Digoxin Approved Drug
DT Modulation Digoxin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Diltiazem Approved Drug
DT Modulation Diltiazem inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Dopamine Approved Drug
DT Modulation Dopamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Doxazosin Approved Drug
DT Modulation Doxazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Doxycycline Approved Drug
DT Modulation Doxycycline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Efavirenz Approved Drug
DT Modulation Efavirenz inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Eflornithine Approved Drug
DT Modulation Eflornithine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Enalapril Approved Drug
DT Modulation Enalapril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ergotamine Approved Drug
DT Modulation Ergotamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ergotidine Approved Drug
DT Modulation Ergotidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Erythromycin Approved Drug
DT Modulation Erythromycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Esmolol Approved Drug
DT Modulation Esmolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Etoposide Approved Drug
DT Modulation Etoposide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Felodipine Approved Drug
DT Modulation Felodipine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Fenofibrate Approved Drug
DT Modulation Fenofibrate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Fentanyl Approved Drug
DT Modulation Fentanyl inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Fluorouracil Approved Drug
DT Modulation Fluorouracil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Fluphenazine Approved Drug
DT Modulation Fluphenazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Flutamide Approved Drug
DT Modulation Flutamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Folic acid Approved Drug
DT Modulation Folic acid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Furosemide Approved Drug
DT Modulation Furosemide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Gabapentin Approved Drug
DT Modulation Gabapentin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ganciclovir Approved Drug
DT Modulation Ganciclovir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Glipizide Approved Drug
DT Modulation Glipizide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Glucosamine Approved Drug
DT Modulation Glucosamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Haloperidol Approved Drug
DT Modulation Haloperidol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Hydralazine Approved Drug
DT Modulation Hydralazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Hydrochlorothiazide Approved Drug
DT Modulation Hydrochlorothiazide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ibuprofen Approved Drug
DT Modulation Ibuprofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Imipramine Approved Drug
DT Modulation Imipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ketoprofen Approved Drug
DT Modulation Ketoprofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Levodopa Approved Drug
DT Modulation Levodopa inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Levofloxacin Approved Drug
DT Modulation Levofloxacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Levothyroxine Approved Drug
DT Modulation Levothyroxine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Lidocaine Approved Drug
DT Modulation Lidocaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Loperamide Approved Drug
DT Modulation Loperamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Loratadine Approved Drug
DT Modulation Loratadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Mannitol Approved Drug
DT Modulation Mannitol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Meclizine Approved Drug
DT Modulation Meclizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Mepenzolate Approved Drug
DT Modulation Mepenzolate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Methimazole Approved Drug
DT Modulation Methimazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Methotrexate Approved Drug
DT Modulation Methotrexate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Methyldopa Approved Drug
DT Modulation Methyldopa inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Metoclopramide Approved Drug
DT Modulation Metoclopramide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Metoprolol Approved Drug
DT Modulation Metoprolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Mianserin Approved Drug
DT Modulation Mianserin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Morphine Approved Drug
DT Modulation Morphine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Naltrexone Approved Drug
DT Modulation Naltrexone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Nandrolone Approved Drug
DT Modulation Nandrolone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Ondansetron Approved Drug
DT Modulation Ondansetron inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Orciprenaline Approved Drug
DT Modulation Orciprenaline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Orphenadrine Approved Drug
DT Modulation Orphenadrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Oxprenolol Approved Drug
DT Modulation Oxprenolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Paclitaxel Approved Drug
DT Modulation Paclitaxel inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Papaverine Approved Drug
DT Modulation Papaverine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Phenobarbital Approved Drug
DT Modulation Phenobarbital inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Phenytoin Approved Drug
DT Modulation Phenytoin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Pilocarpine Approved Drug
DT Modulation Pilocarpine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Pravastatin Approved Drug
DT Modulation Pravastatin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Prednisone Approved Drug
DT Modulation Prednisone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Probenecid Approved Drug
DT Modulation Probenecid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Prochlorperazine Approved Drug
DT Modulation Prochlorperazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Promazine Approved Drug
DT Modulation Promazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Promethazine Approved Drug
DT Modulation Promethazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Propafenone Approved Drug
DT Modulation Propafenone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Propofol Approved Drug
DT Modulation Propofol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Propranolol Approved Drug
DT Modulation Propranolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Risperidone Approved Drug
DT Modulation Risperidone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Scopolamine Approved Drug
DT Modulation Scopolamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Sotalol Approved Drug
DT Modulation Sotalol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Spironolactone Approved Drug
DT Modulation Spironolactone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Sulfasalazine Approved Drug
DT Modulation Sulfasalazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Sulindac Approved Drug
DT Modulation Sulindac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tamoxifen Approved Drug
DT Modulation Tamoxifen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Terazosin Approved Drug
DT Modulation Terazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Terbutaline Approved Drug
DT Modulation Terbutaline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tetracycline Approved Drug
DT Modulation Tetracycline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Theophylline Approved Drug
DT Modulation Theophylline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Timolol Approved Drug
DT Modulation Timolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Tramadol Approved Drug
DT Modulation Tramadol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Trihexyphenidyl Approved Drug
DT Modulation Trihexyphenidyl inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Trimethoprim Approved Drug
DT Modulation Trimethoprim inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Trimipramine Approved Drug
DT Modulation Trimipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Troglitazone Approved Drug
DT Modulation Troglitazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Valproic Acid Approved Drug
DT Modulation Valproic Acid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Vancomycin Approved Drug
DT Modulation Vancomycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Vinblastine Approved Drug
DT Modulation Vinblastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Warfarin Approved Drug
DT Modulation Warfarin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Zanamivir Approved Drug
DT Modulation Zanamivir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Zidovudine Approved Drug
DT Modulation Zidovudine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Dolutegravir Approved Drug
DT Modulation Dolutegravir inhibits the transportation of Metformin by SLC22A1 [30]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Caspofungin Approved Drug
DT Modulation Caspofungin inhibits the transportation of Tetraethyl by SLC22A1 [31]
Affected Drug/Substrate Tetraethyl Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Pindolol Approved Drug
DT Modulation Pindolol inhibits the transportation of Tetraethylammonium by SLC22A1 [15]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OCT1
Exogenous Factor Rocuronium Approved Drug
DT Modulation Rocuronium inhibits the transportation of Tributylmethylammonium by SLC22A1 [32]
Affected Drug/Substrate Tributylmethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT1
Exogenous Factor 2-Methoxyestradiol Drug in Phase 2 Trial
DT Modulation 2-Methoxyestradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Acecainide Discontinued Drug
DT Modulation Acecainide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Bucindolol Drug in Phase 2/3 Trial
DT Modulation Bucindolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Epinephrine Drug in Preclinical Test
DT Modulation Epinephrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Gallopamil Drug in Phase 2 Trial
DT Modulation Gallopamil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Melagatran Drug in Phase 3 Trial
DT Modulation Melagatran inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Sodium taurocholate Drug in Phase 1/2 Trial
DT Modulation Sodium taurocholate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Terfenadine Drug Withdrawn
DT Modulation Terfenadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor 4-Androstene-3-17-Dione Investigative Drug
DT Modulation 4-Androstene-3-17-Dione inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Agmatine Investigative Drug
DT Modulation Agmatine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Arcaine Investigative Drug
DT Modulation Arcaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Choline Investigative Drug
DT Modulation Choline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Normetanephrine Investigative Drug
DT Modulation Normetanephrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Phenazone Investigative Drug
DT Modulation Phenazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1 [6]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT1
Exogenous Factor Green tea Natural Product
DT Modulation Green tea inhibits the transportation of Metformin by SLC22A1 [33]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-OCT1
Exogenous Factor Beclomethasone dipropionate Approved Drug
DT Modulation Beclomethasone dipropionate inhibits the transportation of Agonist salbutamol by SLC22A1 [34]
Affected Drug/Substrate Agonist salbutamol Modulation Type Inhibition
Exogenous Factor Eltrombopag Approved Drug
DT Modulation Eltrombopag inhibits the transportation of Tetraethylammonium by SLC22A1 [9]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Exogenous Factor Sodium butyrate Drug in Phase 2/3 Trial
DT Modulation Butyrate inhibits histone deacetylase, which then enhances Sorafenib's transportation via increasing the histone acethylation level of SLC22A1 [35]
Affected Drug/Substrate Sorafenib Modulation Type Inducer
Cell System Human embryonal rhabdomyosarcoma cells
Exogenous Factor Decitabine Approved Drug
DT Modulation Decitabine inhibits DNA methyltransferase, which then enhances Sorafenib's transportation via downregulating the hypermethylation in SLC22A1's promoter [35]
Affected Drug/Substrate Sorafenib Modulation Type Inducer
Cell System Human embryonal rhabdomyosarcoma cells
Exogenous Factor Carvedilol Approved Drug
DT Modulation Carvedilol inhibits the activity of SLC22A1 [36]
Exogenous Factor Crizotinib Approved Drug
DT Modulation Crizotinib inhibits the activity of SLC22A1 [37]
Exogenous Factor Dexamethasone Approved Drug
DT Modulation Dexamethasone induces the activity of SLC22A1 [38]
Exogenous Factor Insulin Approved Drug
DT Modulation Insulin induces the activity of SLC22A1 [39]
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the activity of SLC22A1 [40]
Exogenous Factor Pyrazinamide Approved Drug
DT Modulation Pyrazinamide inhibits the activity of SLC22A1 [41]
Exogenous Factor Sparfloxacin Approved Drug
DT Modulation Sparfloxacin inhibits the activity of SLC22A1 [42]
References
1 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
2 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
3 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
4 Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61.
5 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
6 Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42.
7 Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther. 2000 Mar;292(3):1146-52.
8 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
9 Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
10 Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2011 Dec;11(6):400-11.
11 Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 2007 Jun;37(6):618-34.
12 Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1). J Med Chem. 2017 Apr 13;60(7):2685-2696.
13 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
14 Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 Jun;57(6):1463-9.
15 Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98.
16 Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. Life Sci. 2007 Aug 2;81(8):664-72.
17 Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307.
18 Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21.
19 Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. Xenobiotica. 2019 Mar;49(3):363-374.
20 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
21 Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
22 Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34.
23 Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability. Biochem Biophys Res Commun. 2001 Nov 23;289(1):130-6.
24 Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011 Mar;89(3):416-21.
25 Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008 Mar;106(3):435-43.
26 Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
27 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
28 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
29 Modulation of organic cation transport and lipid fluidity by benzyl alcohol in rat renal brush-border membranes. Pharm Res. 1996 Jul;13(7):1069-72.
30 In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61.
31 Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82.
32 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
33 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
34 Salbutamol: how does it enter smooth muscle cells? Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):541-6.
35 Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. Hepatology. 2019 Apr 10.
36 Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol. 2011 Jun;178(6):2547-59.
37 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG02908)
38 Study of the effect of the low dosage endotoxin damage on the expression of the organic cation transporter (OCT1) mRNA in hepatocytes. Zhonghua Gan Zang Bing Za Zhi. 2004 Apr;12(4):234-6.
39 Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab Pharmacokinet. 2010;25(4):392-7.
40 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
41 Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6558-6567.
42 Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrob Agents Chemother. 2013 Jun;57(6):2705-11.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.